In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding.

Autor:	Schreiner CN; From the Department of Pediatrics, Boston Medical Center & Boston Children's Hospital, Boston, Massachusetts., Ahlfors CE; Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California., Wong RJ; Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California., Stevenson DK; Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California., Clarke DF; Department of Pediatrics, Boston Medical Center, Boston, Massachusetts., Mirochnick M; Department of Pediatrics, Boston Medical Center, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	The Pediatric infectious disease journal [Pediatr Infect Dis J] 2018 Sep; Vol. 37 (9), pp. 908-909.
DOI:	10.1097/INF.0000000000002011
Abstrakt:	We performed an in vitro evaluation of the effect of maraviroc or dolutegravir on bilirubin to albumin binding. At typical treatment and low albumin concentrations, maraviroc had no impact, while dolutegravir affected bilirubin to albumin binding to an equivalent extent as sulfisoxazole. However in vivo, neither is likely to significantly impact bilirubin to albumin binding because of their low concentrations relative to albumin.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu